Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Multi-Center, Dose Escalation Trial To Assess The Safety And Effectiveness Of Bucillamine On Urinary Cystine Excretion And Cystine Capacity In Patients With Cystinuria

Next Previous
X
Search
Trial Profile

Phase 2 Multi-Center, Dose Escalation Trial To Assess The Safety And Effectiveness Of Bucillamine On Urinary Cystine Excretion And Cystine Capacity In Patients With Cystinuria

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bucillamine (Primary)
  • Indications Cystinuria
  • Focus Adverse reactions; Proof of concept
  • Sponsors Revive Therapeutics

    • Most Recent Events

    • 26 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 26 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 21 Dec 2016 According to a Revive Therapeutics media release, company has engaged NYU School of Medicine as one of the Company's clinical sites in this study and this study is expected to be completed by Q2 of 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top